S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
S&P 500   4,577.11
DOW   35,368.47
QQQ   370.55
Is Lowe’s A Buy On Pre-Earnings Weakness? 
Has Sherwin-Williams Company Lost Its Luster? 
Bed Bath & Beyond Stock is Pricing Right
MarketBeat Podcast: Market Volatility and Commodites Options
Microsoft buys game maker Activision Blizzard for about $70B
Truist cuts down overdraft fees, joining other big banks
Polish chief auditor seeks to question leader over spying
NASDAQ:ARWR

Arrowhead Pharmaceuticals Earnings Date, Estimates, & History

$54.13
-3.68 (-6.37%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$54.02
▼
$56.47
50-Day Range
$54.13
▼
$76.60
52-Week Range
$54.02
▼
$93.66
Volume
587,820 shs
Average Volume
651,838 shs
Market Capitalization
$5.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.25

Earnings Summary

Upcoming
Earnings Date
Feb. 3
Estimated

Actual EPS
(Nov. 22)
-$0.61
Missed By -$0.65

Consensus EPS
(Nov. 22)
$0.04

Last Year's Q4 EPS
(11/22/2020)
-$0.48

Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

Arrowhead Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Arrowhead Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20222($0.47)($0.05)($0.26)
Q2 20222($0.56)($0.02)($0.29)
Q3 20223($0.56)$0.03($0.27)
Q4 20223($0.65)$0.24($0.26)
FY 202210($2.24)$0.20($1.08)
Q1 20231($0.73)($0.73)($0.73)
Q2 20231($0.84)($0.84)($0.84)
Q3 20231($0.87)($0.87)($0.87)
Q4 20231($0.98)($0.98)($0.98)
FY 20234($3.42)($3.42)($3.42)

ARWR Earnings Information

Arrowhead Pharmaceuticals last posted its quarterly earnings data on November 22nd, 2021. The biotechnology company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.65. Arrowhead Pharmaceuticals has generated ($1.36) earnings per share over the last year (($1.36) diluted earnings per share). Earnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($0.69) to ($1.88) per share. Arrowhead Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 3rd, 2022 based off prior year's report dates.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
2/3/2022
(Estimated)		        
11/22/20219/30/2021$0.04($0.61)($0.65)($0.61)    
8/4/20216/30/2021($0.08)($0.29)($0.21)($0.29)$50.20 million$45.89 million    
5/3/20213/31/2021($0.09)($0.26)($0.17)($0.26)$39.42 million$32.81 million  
2/3/202112/31/2020$1.00($0.20)($1.20)($0.20)$157.48 million$21.30 million  
11/22/20209/30/2020$0.34($0.48)($0.82)($0.48)$85.13 million$7.63 million  
8/5/20206/30/2020($0.07)($0.13)($0.06)($0.13)$38.76 million$27.38 million  
5/7/20203/31/2020($0.11)($0.20)($0.09)($0.20)$21.90 million$23.53 million  
2/5/202012/31/2019$0.04($0.03)($0.07)($0.03)$36.63 million$29.46 million  
11/25/2019Q4$0.14$0.11($0.03)$0.11$36.97 million$43.29 million  
8/5/2019Q3 2019$0.34$0.21($0.13)$0.21$59.05 million$42.70 million  
5/8/20193/31/2019$0.22$0.24+$0.02$0.24$45.78 million$48.15 million  
2/7/201912/31/2018$0.76$0.13($0.63)$0.13$90.88 million$34.66 million
12/11/2018Q4 2018($0.17)($0.12)+$0.05($0.12)$3.73 million$11.26 million  
8/7/2018Q3 2018($0.19)($0.18)+$0.01($0.18)$0.62 million$0.73 million
5/8/2018Q2 2018($0.19)($0.18)+$0.01($0.18)$4.04 million$0.65 million
2/9/2018Q1 2018($0.14)($0.18)($0.04)($0.18)$8.71 million$3.51 million  
12/12/2017Q4 2017($0.12)($0.14)($0.02)($0.14)$7.32 million$8.71 million
8/3/2017Q3 2017($0.13)($0.07)+$0.06($0.07)$5.29 million$9.34 million  
5/3/2017Q2 2017($0.1230)($0.08)+$0.0430($0.08)$4.19 million$8.99 million  
2/6/2017Q117($0.20)($0.17)+$0.03($0.17)$13.24 million$4.37 million  
12/14/2016Q4 2016($0.33)($0.31)+$0.02($0.28)$0.04 million$0.03 million
8/9/2016Q316($0.37)($0.32)+$0.05($0.32)$0.05 million$39.58 million
5/10/2016Q216($0.37)($0.35)+$0.02($0.35)$0.26 million$0.04 million  
2/9/2016Q1($0.41)($0.32)+$0.09($0.32)$0.29 million$0.04 million
12/14/2015Q415($0.39)($0.42)($0.03)($0.42)$0.14 million$0.04 million  
8/4/2015Q315($0.38)($0.27)+$0.11($0.27)$0.11 million$0.12 million
5/11/2015Q214($0.35)($0.33)+$0.02($0.15)$110.00 million$43.75 million  
2/9/2015Q114($0.32)($0.41)($0.09)($0.41)$0.24 million$0.17 million
11/25/2014Q413($0.25)($0.33)($0.08)($0.24)$0.04 million$0.04 million  
8/12/2014Q313($0.22)($0.22)($0.22)$0.04 million$0.04 million  
5/6/2014Q2 2014($0.18)($0.31)($0.13)($0.31)$0.05 million$0.04 million
2/4/2014Q1 2014($0.18)($0.28)($0.10)($0.28)$0.05 million$0.04 million
12/18/2013Q4($0.23)($0.43)($0.20)  
8/7/2013Q3 2013($0.22)($0.23)($0.01)($0.23)$0.50 million$0.04 million
5/9/2013Q2 2013($0.41)($0.41)($0.41)$0.04 million  
2/13/2013Q1 2013($0.33)($0.33)  
12/20/2012Q4 2012($0.43)($0.43)
8/13/2012Q3 2012($0.71)($0.71)($0.71)
5/8/2012Q2 2012($0.44)($0.44)($0.38)
2/9/2012Q1 2012($0.25)($0.25)($0.25)
12/20/2011Q4 2011($0.39)($0.39)($0.39)
8/8/2011Q3 2011($0.20)($0.26)($0.06)($0.27)
5/12/2011Q2 2011($0.20)($0.18)+$0.02($0.73)
2/10/2011Q1 2011($0.20)($0.20)($0.20)
12/22/2010Q4 2010($0.30)($0.28)+$0.02($0.28)
8/12/2010Q3 2010($0.50)($0.06)+$0.44($0.06)
5/13/2010Q2 2010($0.40)($0.33)+$0.07($0.33)
2/11/2010Q1 2010($0.30)($0.30)($0.30)
12/22/2009Q4 2009($0.60)($0.60)($0.60)
8/10/2009Q3 2009($0.60)($0.60)($0.60)
5/15/2009Q2 2009($1.20)($1.20)($1.20)
2/9/2009Q1 2009($1.90)($1.90)($1.90)
12/15/2008Q4 2008($2.14)($2.14)($2.14)
8/11/2008Q3 2008($1.90)($1.90)($1.90)
2/11/2008Q1 2008($1.40)($1.40)($1.40)
(Earnings results data provided by Zacks Investment Research)












Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earnings Frequently Asked Questions

When is Arrowhead Pharmaceuticals's earnings date?

Arrowhead Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 3rd, 2022 based off last year's report dates. Learn more on ARWR's earnings history

Did Arrowhead Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) missed the analysts' consensus estimate of $0.04 by $0.65 with a reported earnings per share (EPS) of ($0.61). Learn more on ARWR's earnings details

How can I listen to Arrowhead Pharmaceuticals's earnings conference call?

The conference call for Arrowhead Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Arrowhead Pharmaceuticals's conference call transcript?

The conference call transcript for Arrowhead Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Arrowhead Pharmaceuticals generate each year?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded annual revenue of $138.29 million.

How much profit does Arrowhead Pharmaceuticals generate each year?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$140.85 million. ARWR has generated -$1.36 earnings per share over the last four quarters.

What is Arrowhead Pharmaceuticals's EPS forecast for next year?

Arrowhead Pharmaceuticals's earnings are expected to decrease from ($0.69) per share to ($1.88) per share in the next year.

This page was last updated on 1/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.